ANZCA Examinations

Australian and New Zealand College of Anaesthetists. Comprehensive coverage of the Primary and Final Fellowship examinations.

Primary Exam

Pharmacology, Physiology, and Physics/Measurement principles.

Basic Sciences
88
Final Exam

Clinical anaesthesia, perioperative medicine, and pain management.

Clinical Focus
154
Oral Exam Topics

High-yield prompts and topic coverage for oral examination preparation.

Oral Exam
250
250Topics Available
Primaryand Final coverage
250 results
ANZCA

Acid-Base Physiology

Acid-base homeostasis is maintained through the interplay of three major buffer systems: bicarbonate (primary), phosphate, and protein buffers. The Henderson-Hasselbalch equation (pH = pKa + log[HCO₃⁻/(0.03 × PCO₂)])...

Respiratory Physiology31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Acid-Base Physiology

Acid-base balance maintains arterial pH 7.35-7.45 through chemical buffering, respiratory compensation, and renal regulation. pH: Negative logarithm of [H⁺]; normal [H⁺] 40 nEq/L (35-45); pH 7.40 = [H⁺] 40 nEq/L; pH...

Physiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Adductor Canal Block

Roof (Superficial Wall): Sartorius muscle : Forms the roof of the canal for most of its length Fascial thickening : Strong fascia covering sartorius contributes to canal formation Attachment : Fascia blends with...

Lower Limb Regional3 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Airway Assessment

Systematic airway assessment identifies 80-90% of difficult airways but has limited positive predictive value ( 10-15%), meaning many predicted difficult airways are easily managed and some predicted easy airways...

General Clinical2 Feb 2026
ANZCA Final
Airway Management
High evidence
ANZCA Final Written
+1
ANZCA

Airway Fire in the Operating Room - Prevention and Management

Immediate Management (Critical First 60 Seconds): Simultaneously: Remove all airway devices (ETT, LMA, nasal tube, etc.) Disconnect oxygen source - flood circuit with air Pour sterile saline into airway (300-500 mL if...

Anaesthetic Crisis Management3 Feb 2026
Anaesthesia
ANZCA Final
A - ANZCA Guidelines evidence
ANZCA Final Written
ANZCA

Alfentanil and Sufentanil Pharmacology

Alfentanil and sufentanil are synthetic 4-anilidopiperidine opioid agonists derived from fentanyl, sharing its characteristic phenylpiperidine structure but with distinct pharmacokinetic profiles that determine their...

Intravenous Opioid Analgesics1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Anaesthesia for Aortic Arch Surgery

Aortic arch surgery requires deep hypothermic circulatory arrest (DHCA) with or without selective cerebral perfusion (SCP) . Indications : Aortic aneurysm, acute dissection (Type A), atherosclerotic disease. Core...

Vascular3 Feb 2026
ANZCA Final
Vascular Surgery
High evidence
ANZCA Final Written
+2
ANZCA

Anaesthesia for Aortic Surgery

Aortic surgery ranges from open repair (high risk, physiological insult) to endovascular stent grafting (EVAR/TEVAR, less invasive but still significant). Anatomy: Ascending aorta (coronary arteries, aortic valve),...

Vascular2 Feb 2026
ANZCA Final
Vascular Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Awake Craniotomy

Awake craniotomy allows direct cortical mapping of speech, motor, and sensory areas during resection of lesions near eloquent cortex. Indications : Low-grade gliomas, epileptogenic foci, deep brain stimulation...

Neurosurgical3 Feb 2026
ANZCA Final
Neurosurgery
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Burns Patients

Burns anaesthesia presents challenges: airway management (inhalation injury, swelling), fluid resuscitation (Parkland formula: 4 mL/kg/%TBSA in 24 hours - half in first 8 hours), temperature control (massive heat loss...

Trauma Anaesthesia2 Feb 2026
ANZCA Final
Trauma
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Cardiac Valve Surgery

Valve surgery requires understanding of hemodynamic goals specific to each lesion . Aortic stenosis (AS): Maintain sinus rhythm, normal-high preload, avoid hypotension/tachycardia, treat dynamic obstruction with...

Cardiothoracic2 Feb 2026
ANZCA Final
Cardiac Surgery
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Carotid Artery Stenting (CAS)

Carotid artery stenting (CAS) is a minimally invasive alternative to carotid endarterectomy (CEA) for carotid stenosis. Indications : High surgical risk (medical comorbidities, hostile neck, previous CEA/restenosis),...

Vascular3 Feb 2026
ANZCA Final
Vascular Surgery
High evidence
ANZCA Final Written
+2
ANZCA

Anaesthesia for Carotid Endarterectomy

Carotid endarterectomy (CEA) removes atherosclerotic plaque to prevent stroke. Indications : Symptomatic carotid stenosis 50-70% (recent TIA/stroke), asymptomatic 80% (selective). Monitoring : Arterial line, cerebral...

Vascular2 Feb 2026
ANZCA Final
Vascular Surgery
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Cerebral Aneurysm Clipping

Cerebral aneurysm clipping requires strict blood pressure control (avoid hypertension pre-clipping, maintain normotension/mild hypotension during dissection), brain relaxation (mannitol, CSF drainage), and readiness...

Neurosurgical2 Feb 2026
ANZCA Final
Neurosurgery
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Coronary Artery Bypass Grafting

Coronary artery bypass grafting (CABG) requires myocardial protection during ischemic arrest, hemodynamic optimization , and management of bleeding/coagulopathy . Preoperative : Continue antiplatelet agents (aspirin),...

Cardiothoracic2 Feb 2026
ANZCA Final
Cardiac Surgery
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Day Surgery

Day surgery (ambulatory surgery) requires rapid, smooth emergence , effective analgesia allowing oral intake and mobility, minimal PONV , and safe discharge . Patient selection : ASA I-III generally acceptable, BMI...

General Surgery2 Feb 2026
ANZCA Final
Ambulatory Anaesthesia
High evidence
ANZCA Final Written
ANZCA

Anaesthesia for Deep Brain Stimulation

Deep brain stimulation (DBS) requires awake intraoperative assessment for optimal electrode placement (microelectrode recording + clinical testing). Anaesthesia strategy : light general anaesthesia for frame...

Neurosurgical2 Feb 2026
ANZCA Final
Neurosurgery
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Dental Extractions

Dental extraction anaesthesia requires managing the "shared airway" with the dental surgeon while ensuring patient safety and comfort. Key considerations: (1) Airway management : Nasal intubation, reinforced LMA...

Oral and Maxillofacial3 Feb 2026
ANZCA Final
Dental Anaesthesia
A evidence
ANZCA Final Written
+2
ANZCA

Anaesthesia for Endoscopic Sinus Surgery

Functional Endoscopic Sinus Surgery (FESS) is a minimally invasive technique for treating chronic rhinosinusitis, nasal polyps, and skull base pathology. Key anaesthetic challenges include:

Otorhinolaryngology3 Feb 2026
ANZCA Final
ENT Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Head Injury

Traumatic brain injury (TBI) affects 700 per 100,000 population annually in Australia, with anaesthetic management focused on preventing secondary brain injury by optimizing cerebral oxygenation and perfusion....

Neurosurgical2 Feb 2026
ANZCA Final
Neuroanaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Heart Transplantation

Heart transplantation is the gold standard treatment for end-stage heart failure refractory to medical/device therapy. Indications : Dilated cardiomyopathy (50-60%), ischemic cardiomyopathy (25-35%), congenital heart...

Cardiothoracic3 Feb 2026
ANZCA Final
Cardiac Surgery
High evidence
ANZCA Final Written
+2
ANZCA

Anaesthesia for Laparoscopic Surgery

Laparoscopic surgery presents unique physiological challenges: pneumoperitoneum (CO₂ insufflation 12-15 mmHg) increases intra-abdominal pressure causing cardiovascular effects (↓venous return initially, then ↑SVR and...

General Surgery2 Feb 2026
ANZCA Final
General Surgery
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Laser Eye Surgery

Comprehensive guide to anaesthesia for PRK, LASIK, sedation requirements, and patient fixation for ANZCA Fellowship examination

Ophthalmic Surgery
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Anaesthesia for Lung Resection

Lung resection includes pneumonectomy (entire lung), lobectomy (single lobe), segmentectomy/wedge (sublobar), and sleeve resection (bronchoplastic). Indications : Primary lung cancer (NSCLC 85%, SCLC 15%),...

Cardiothoracic3 Feb 2026
ANZCA Final
Thoracic Surgery
High evidence
ANZCA Final Written
+2
ANZCA

Anaesthesia for Lung Transplantation

Lung transplantation is performed for end-stage lung disease refractory to medical therapy. Indications : COPD (30-35%), interstitial lung disease (25-30%), cystic fibrosis (15-20%), pulmonary hypertension (5-10%),...

Cardiothoracic3 Feb 2026
ANZCA Final
Cardiothoracic Surgery
High evidence
ANZCA Final Written
+2
ANZCA

Anaesthesia for Middle Ear Surgery

Middle ear surgery encompasses tympanoplasty, mastoidectomy, stapedectomy, and cholesteatoma surgery. Key anaesthetic considerations include:

Otorhinolaryngology3 Feb 2026
ANZCA Final
ENT Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Myasthenia Gravis

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder causing fatigable muscle weakness due to anti-acetylcholine receptor (AChR) antibodies (80-85%) or anti-MuSK antibodies (5-8%). Anaesthetic challenges :...

Neurosurgical3 Feb 2026
ANZCA Final
Neurology
High evidence
ANZCA Final Written
+2
ANZCA

Anaesthesia for Obesity

Obesity (BMI 30 kg/m²) affects 30% of Australian adults and presents significant anaesthetic challenges due to physiological changes including reduced functional residual capacity (FRC), increased airway resistance,...

General Clinical2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Ophthalmic Trauma

Comprehensive guide to anaesthesia for open globe injuries, orbital fractures, and intraocular pressure management for ANZCA Fellowship examination

Ophthalmic Trauma
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Anaesthesia for Organ Transplantation

Organ transplantation presents unique challenges: Kidney transplant (most common, end-stage renal disease) - avoid nephrotoxins, maintain perfusion, manage hyperkalemia, avoid hypotension post-anastomosis. Liver...

General Surgery2 Feb 2026
ANZCA Final
Transplantation
High evidence
ANZCA Final Written
+2
ANZCA

Anaesthesia for Parotid Surgery

Comprehensive guide to anaesthesia for parotidectomy including facial nerve monitoring, Frey syndrome, and sialogogue use for ANZCA Fellowship examination

ENT Surgery
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Anaesthesia for Patients with Pacemakers and ICDs

Patients with cardiac implantable electronic devices (CIEDs) including pacemakers and implantable cardioverter-defibrillators (ICDs) require systematic perioperative management to prevent device malfunction from...

Cardiac Anaesthesia1 Feb 2025
ANZCA Final
Clinical Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Posterior Fossa Surgery

Posterior fossa surgery (sitting/prone park bench position) carries unique risks: venous air embolism (VAE, 20-40% incidence, 1% clinically significant), trigeminal-cardiac reflex (TCR, severe bradycardia/asystole...

Neurosurgical2 Feb 2026
ANZCA Final
Neurosurgery
High evidence
ANZCA Final Written
ANZCA

Anaesthesia for Pyloric Stenosis

Infantile hypertrophic pyloric stenosis (IHPS) is a medical emergency requiring correction of hypochloraemic hypokalaemic metabolic alkalosis BEFORE surgery - it is NOT a surgical emergency. Presentation is typically...

Paediatric Anaesthesia1 Feb 2026
ANZCA Final
Paediatric Anaesthesia
High evidence
ANZCA Final Written
ANZCA

Anaesthesia for Radical Neck Dissection

Comprehensive guide to anaesthesia for radical neck dissection including airway compromise, carotid protection, and shoulder dysfunction for ANZCA Fellowship examination

Head and Neck Surgery
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Anaesthesia for Renal Transplantation

for ANZCA Finals : - ESRD Physiology : Cardiovascular disease (leading cause of death), anaemia, platelet dysfunction, hyperkalaemia, metabolic acidosis, altered drug pharmacokinetics - Preoperative : Dialysis within...

Transplant Anaesthesia1 Feb 2026
ANZCA Final
Transplant Anaesthesia
Level II-III evidence
ANZCA Final Examination
ANZCA

Anaesthesia for Salivary Gland Surgery

Salivary gland surgery requires meticulous attention to the facial nerve (parotid surgery) and airway management. Key considerations: (1) Facial nerve preservation : Electromyography (EMG) monitoring mandatory for...

Otorhinolaryngology3 Feb 2026
ANZCA Final
ENT Anaesthesia
A evidence
ANZCA Final Written
+2
ANZCA

Anaesthesia for Spinal Surgery

Spinal surgery anaesthesia requires positioning considerations (prone/lateral/sitting), neurophysiological monitoring (SSEPs/MEPs), blood loss management (cell salvage, controlled hypotension), and air embolism...

Neurosurgical2 Feb 2026
ANZCA Final
Neurosurgery
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for the Septic Patient

Sepsis is life-threatening organ dysfunction caused by dysregulated host response to infection, with septic shock defined as sepsis with persistent hypotension requiring vasopressors despite adequate fluid...

General Clinical2 Feb 2026
ANZCA Final
Critical Care
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Thoracic Aortic Surgery

Thoracic aortic surgery includes open repair and endovascular (TEVAR) approaches. Open repair requires left heart bypass (partial) or deep hypothermic circulatory arrest (DHCA) for arch/proximal descending, with...

Cardiothoracic2 Feb 2026
ANZCA Final
Cardiothoracic Surgery
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Tonsillectomy

Tonsillectomy presents unique anaesthetic challenges due to the shared airway with the surgeon, risk of post-tonsillectomy haemorrhage (PTH) , and frequent paediatric population. Key considerations include:

Otorhinolaryngology3 Feb 2026
ANZCA Final
ENT Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Trauma

Trauma is the leading cause of death in Australians aged 1-44 years, with major trauma requiring coordinated multidisciplinary care including damage control resuscitation (DCR) principles. Primary survey follows ABCDE...

General Clinical2 Feb 2026
ANZCA Final
Trauma Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia for Vitreoretinal Surgery

Comprehensive guide to anaesthesia for scleral buckle, pneumatic retinopexy, gas tamponade, and complex vitrectomy for ANZCA Fellowship examination

Vitreoretinal Surgery
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Anaesthesia in Liver Failure

Liver failure presents complex perioperative challenges due to impaired synthetic function, coagulopathy, fluid shifts, and multi-organ involvement. Classification: Acute liver failure (ALF—encephalopathy within 8...

General Clinical2 Feb 2026
ANZCA Final
Hepatology
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia in Renal Failure

Chronic kidney disease (CKD) stage 4-5 (eGFR <30 mL/min) and acute kidney injury (AKI) present significant perioperative risks due to fluid overload, electrolyte abnormalities, coagulopathy, and altered drug...

General Clinical2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia in the Elderly

Ageing physiology significantly impacts anaesthetic management due to reduced functional reserve in cardiovascular, respiratory, renal, hepatic, and neurological systems. Pharmacokinetic changes include reduced lean...

General Clinical2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Anaesthesia in the Elderly

Geriatric anaesthesia (age 65-70) requires understanding of age-related physiological changes and pharmacokinetic/pharmacodynamic alterations . Cardiovascular : Reduced compliance, diastolic dysfunction, fixed stroke...

General2 Feb 2026
ANZCA Final
Geriatric Medicine
High evidence
ANZCA Final Written
ANZCA

Anaesthetic Machine

Modern anaesthetic machines integrate gas delivery, vaporization, breathing systems, and monitoring with multiple safety features. Gas supply: Central pipeline (oxygen 400 kPa, air, nitrous oxide) or cylinders (oxygen...

Anaesthetic Equipment2 Feb 2026
ANZCA Primary
Equipment
High evidence
ANZCA Primary Written
+1
ANZCA

Anaesthetic Monitoring Standards

ANZCA Professional Standard PS41 (Anaesthetic Machine Monitoring Standards) mandates minimum monitoring for all patients undergoing general, regional, or sedation anaesthesia. Continuous monitoring: Inspired and...

Patient Monitoring2 Feb 2026
ANZCA Primary
Equipment
High evidence
ANZCA Primary Written
+1
ANZCA

Atracurium and Cisatracurium: Pharmacology

Atracurium is a benzylisoquinolinium non-depolarizing neuromuscular blocker with unique Hofmann elimination (chemical degradation at physiological pH and temperature) and ester hydrolysis by plasma cholinesterases....

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
ANZCA

Atracurium Pharmacology

Atracurium besylate is an intermediate-acting, non-depolarizing benzylisoquinolinium neuromuscular blocking agent (NMBA) characterised by organ-independent elimination through Hofmann elimination (spontaneous chemical...

Benzylisoquinolinium Neuromuscular Blocking Agents31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Atropine Pharmacology

Atropine is a naturally occurring tropane alkaloid and the prototypical competitive muscarinic acetylcholine receptor antagonist. As a tertiary amine with a pKa of 9.7, it crosses the blood-brain barrier and produces...

Muscarinic Antagonists31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Autonomic Nervous System & Cardiovascular Control

The autonomic nervous system (ANS) regulates involuntary functions, divided into sympathetic (thoracolumbar T1-L2, fight-or-flight) and parasympathetic (craniosacral S2-S4, rest-and-digest) divisions. Sympathetic...

Autonomic Nervous System31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Awareness Under Anaesthesia

Accidental awareness during general anaesthesia (AAGA) is the unintended recall of intraoperative events by patients who received general anaesthesia, occurring in approximately 0.1-0.2% of general surgical cases (1-2...

General Clinical2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Awareness Under Anaesthesia and Depth of Anaesthesia Monitoring

Accidental awareness during general anaesthesia (AAGA) is a rare but devastating complication with an incidence of approximately 1:19,000 anaesthetics in the UK (NAP5 data). It is defined as explicit recall of sensory...

General Anaesthesia1 Feb 2026
ANZCA Final
Clinical Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Axillary Block

Axillary brachial plexus block targets the terminal branches of the brachial plexus as they surround the axillary artery in the axilla. Coverage : Forearm, wrist, hand (entire upper limb below mid-humerus)....

Upper Limb Regional3 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Bariatric Surgery Anaesthesia

Mechanical Alterations: Increased intra-abdominal pressure : Elevated by 5-15 mmHg above normal due to central adiposity, reducing diaphragmatic excursion Decreased FRC : Reduced by 30-50% in morbid obesity (BMI 40...

Special Populations3 Feb 2026
ANZCA Final
Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Beach Chair Position Anaesthesia

Beach chair position (BCP) involves elevating the head and torso 30-70 degrees from supine with legs lowered, primarily used for shoulder surgery. Physiological effects : Gravitational effects on cerebral perfusion...

Surgical Positioning3 Feb 2026
ANZCA Final
Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Beta-Blockers Pharmacology

Beta-adrenergic receptor antagonists (beta-blockers) competitively inhibit catecholamine binding at beta-adrenoceptors, producing negative chronotropy (reduced heart rate), negative inotropy (reduced contractility),...

Cardiovascular Pharmacology1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Brachial Plexus Blocks

The brachial plexus (C5-T1 roots) provides motor and sensory innervation to the upper limb. Four principal approaches exist for brachial plexus blockade: interscalene (shoulder surgery, 100% phrenic nerve palsy),...

Regional Anaesthesia31 Jan 2025
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Breathing Circuits and Systems

Anaesthetic breathing circuits deliver fresh gas to patient and remove expired CO₂, classified by rebreathing characteristics and presence of CO₂ absorption. Mapleson classification (non-rebreathing): A (Magill):...

Anaesthetic Equipment2 Feb 2026
ANZCA Primary
Equipment
High evidence
ANZCA Primary Written
+1
ANZCA

Bupivacaine

Bupivacaine is a potent, long-acting amide local anaesthetic widely used for neuraxial blocks (epidural, spinal), peripheral nerve blocks, and labour analgesia. Structure: Amide local anaesthetic (pipecoloxylidide),...

Local Anaesthetic Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Caesarean Section Anaesthesia

Caesarean section is the most common major surgical procedure in Australia, with approximately 30-35% of births delivered by caesarean section. Neuraxial anaesthesia (spinal, epidural, or combined spinal-epidural) is...

Obstetric Anaesthesia2 Feb 2026
ANZCA Final
Obstetric Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Calcium Channel Blockers Pharmacology

Calcium channel blockers (CCBs) inhibit voltage-gated L-type calcium channels, reducing calcium influx into cardiac and vascular smooth muscle cells. Classification is based on chemical structure : dihydropyridines...

Cardiovascular Drugs1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Can't Intubate Can't Oxygenate (CICO)

What is it? Can't Intubate Can't Oxygenate (CICO) is a life-threatening airway emergency where tracheal intubation has failed AND oxygenation cannot be achieved via facemask or supraglottic airway (SGA). This...

Crisis Management3 Feb 2026
Anaesthesia
Emergency Medicine
A evidence
+1
ANZCA

Cancer Pain Management - WHO Ladder and Beyond

Cancer pain affects 30-50% of patients during treatment and 70-90% of patients with advanced disease. It is the most feared symptom of cancer and significantly impacts quality of life, function, and psychological...

Cancer Pain3 Feb 2026
ANZCA Final
Pain Medicine
A evidence
ANZCA Final Written
+1
ANZCA

Cancer Surgery and Anaesthesia

What is it? Anaesthesia for cancer surgery requires specialized knowledge of cancer biology, immunosuppression effects, optimal surgical timing, and perioperative considerations that differ significantly from...

Perioperative Medicine3 Feb 2026
Anaesthesia
Perioperative Medicine
A evidence
+1
ANZCA

Capnography - Physics, Waveform Analysis, and Clinical Applications

Capnography is the continuous measurement and graphical display of carbon dioxide (CO₂) concentration in respiratory gases. It utilises infrared absorption spectroscopy at the characteristic CO₂ wavelength of 4.26 μm...

Gas Measurement31 Jan 2026
ANZCA Primary
Equipment-Physics
High evidence
ANZCA Primary Written
+1
ANZCA

Carbon Dioxide Transport

Carbon dioxide (CO2) is transported from tissues to lungs via three mechanisms: dissolved CO2 (5-10%), bicarbonate (60-70%), and carbamino compounds (20-25%). The bicarbonate pathway involves carbonic anhydrase...

Respiratory Physiology31 Jan 2025
Anaesthesia
High evidence
ANZCA Primary Written
ANZCA

Cardiac Cycle & Pressure-Volume Loops

The cardiac cycle consists of systole (isovolumetric contraction, ejection) and diastole (isovolumetric relaxation, filling). Pressure-volume (PV) loops graphically represent left ventricular pressure vs volume...

Cardiovascular Physiology31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Cardiac Tamponade

Cardiac tamponade is life-threatening compression of the heart by fluid (blood, effusion) in the pericardial space impairing diastolic filling and reducing cardiac output. Pathophysiology: Pericardial pressure...

Cardiothoracic2 Feb 2026
ANZCA Final
Cardiac Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Cardiomyoplasty and Skeletal Muscle Ventricle

Cardiomyoplasty is an experimental surgical technique using skeletal muscle to assist or replace cardiac function. Two approaches exist: (1) Dynamic cardiomyoplasty—wrapping the latissimus dorsi muscle around the...

Cardiac Surgery3 Feb 2026
Anaesthesia
Cardiothoracic Surgery
B evidence
ANZCA Final Examination
ANZCA

Cardiopulmonary Bypass Cannulation

Cardiopulmonary bypass (CPB) cannulation establishes extracorporeal circulation for cardiac surgery. Arterial cannulation (ascending aorta 95%, femoral 3%, axillary 2%) delivers oxygenated blood (cannula size: 20-24...

Cardiothoracic2 Feb 2026
ANZCA Final
Cardiac Surgery
High evidence
ANZCA Final Written
+1
ANZCA

Cardiovascular Physiology

The cardiovascular system maintains perfusion to all tissues through coordinated heart function, vascular tone, and blood volume regulation. Cardiac output (CO): 5-6 L/min (HR 60-100 bpm × SV 60-100 mL); determined by...

Organ Physiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Cerebral Blood Flow and Metabolism

Cerebral blood flow (CBF) is tightly regulated to maintain constant oxygen and glucose delivery to the brain, which has high metabolic demand (20% of resting oxygen consumption, 2% of body weight). Normal CBF: 50...

Neurophysiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Cerebrovascular Surgery: AVMs, Moyamoya, and Stroke Revascularisation

Cerebrovascular surgery (AVM resection, Moyamoya bypass, stroke revascularisation) requires meticulous haemodynamic control to maintain cerebral perfusion while avoiding catastrophic complications. Key principles:

Cerebrovascular Surgery3 Feb 2026
ANZCA Final
Neuroanaesthesia
A evidence
ANZCA Final Written
+2
ANZCA

Chronic Pain Assessment

"Pain is an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage."

Pain Medicine2 Feb 2026
ANZCA Final
Pain Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Clinical Governance in Anaesthesia

Comprehensive guide to quality improvement, audit, morbidity meetings, and clinical governance frameworks for ANZCA Fellowship examination

Professional Skills
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Clonidine Pharmacology

Clonidine is a selective alpha-2 (α2) adrenergic receptor agonist with central sympatholytic, sedative, and analgesic properties that make it valuable in perioperative medicine. It is an imidazoline derivative that...

Alpha-2 Adrenergic Receptor Agonists3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+2
ANZCA

Coagulation and Haemostasis

Haemostasis maintains blood fluidity while preventing bleeding through vascular, platelet, and coagulation factors working in concert. Primary haemostasis: Vascular spasm, platelet adhesion (glycoprotein Ib-von...

Blood Physiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Communication Skills in Anaesthesia

Comprehensive guide to difficult conversations, breaking bad news, escalation protocols, and patient-centered communication for ANZCA Fellowship examination Professional Skills component

Professional Skills
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Complex Regional Pain Syndrome (CRPS)

Reflex Sympathetic Dystrophy (RSD): Originally described by Mitchell et al. (1864) in Civil War soldiers with persistent burning pain after nerve injury. The term implied sympathetic nervous system involvement.

Pain Medicine3 Feb 2026
ANZCA Final
Pain Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Congenital Diaphragmatic Hernia (CDH)

CDH is a developmental defect where abdominal contents herniate into the thorax through a defect in the diaphragm, causing pulmonary hypoplasia and pulmonary hypertension. Key anaesthetic principles:

Congenital Anomalies3 Feb 2026
ANZCA Final
Paediatric Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Corticosteroids Pharmacology

Corticosteroids are synthetic analogues of endogenous cortisol with varying ratios of glucocorticoid (anti-inflammatory, metabolic) to mineralocorticoid (sodium retention) activity. In anaesthesia, they are used for...

Corticosteroids1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Day Surgery Anaesthesia

Day surgery (ambulatory surgery) constitutes 70-80% of elective surgical procedures in Australia, requiring rapid recovery, minimal side effects, and safe discharge criteria. Patient selection: ASA 1-2 (selected ASA 3...

General Clinical2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Dental Anaesthesia

Challenges: Airway obstruction : Surgeon's hands and instruments in airway Monitoring difficulty : Face and airway obscured by surgical drapes Limited access : Cannot easily perform laryngoscopy or adjust airway...

Special Populations3 Feb 2026
ANZCA Final
Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Depth of Anaesthesia Monitoring

Depth of anaesthesia (DoA) monitors process electroencephalogram (EEG) signals to assess the hypnotic component of general anaesthesia. The three main technologies are: (1) Bispectral Index (BIS)—algorithm combining...

Primary Examination3 Feb 2026
Anaesthesia
Equipment
A evidence
ANZCA Primary Written
ANZCA

Desflurane: Pharmacology and Clinical Use

Desflurane is a fluorinated methyl ethyl ether with lowest blood/gas partition coefficient (0.42), providing most rapid emergence of volatile agents. Physical properties : High vapor pressure (669 mmHg at 20°C),...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
ANZCA

Dexmedetomidine Pharmacology

Dexmedetomidine is a highly selective alpha-2 adrenoceptor agonist (α2:α1 ratio 1620:1 ) used for sedation in intensive care and procedural settings. It produces "cooperative sedation" via inhibition of noradrenergic...

Alpha-2 Agonists1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Dexmedetomidine: Pharmacology and Clinical Use

Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with sedative, anxiolytic, and analgesic properties. Mechanism : Acts on alpha-2A receptors in locus coeruleus (sedation), spinal cord (analgesia), and...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Diazepam: Pharmacology and Clinical Applications in Anaesthesia

Diazepam is a long-acting benzodiazepine that acts as a positive allosteric modulator at the GABA-A receptor, producing anxiolysis, sedation, amnesia, and anticonvulsant effects. Its clinical utility is limited in...

3 Feb 2026
ANZCA Primary
Pharmacology
+1
ANZCA

Difficult Airway Management

The upper airway consists of the nasal cavity, oral cavity, pharynx, and larynx. Critical anatomical relationships determine the ease or difficulty of airway management:

Resuscitation and Critical Incidents2 Feb 2026
ANZCA Final
Airway Management
High evidence
ANZCA Final Written
+2
ANZCA

Difficult Ventilation - Can't Intubate Can't Ventilate (CICV) Management

Immediate Recognition of Can't Intubate Can't Ventilate (CICV/CICO): Failed intubation: Multiple attempts unsuccessful Failed face mask ventilation: Cannot achieve chest movement, EtCO2, or SpO2 Failed SGA rescue:...

Anaesthetic Crisis Management3 Feb 2026
Anaesthesia
ANZCA Final
A - ANZCA Guidelines evidence
ANZCA Final Written
ANZCA

Direct Oral Anticoagulants (DOACs) Pharmacology

Direct Oral Anticoagulants (DOACs), also termed Non-vitamin K Antagonist Oral Anticoagulants (NOACs), represent a pharmacological revolution in anticoagulation therapy, offering predictable pharmacokinetics, fixed...

Anticoagulants1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

ECG Monitoring in Anaesthesia

Electrocardiography (ECG) monitors cardiac electrical activity through surface electrodes that detect voltage changes generated by myocardial depolarization and repolarization. The signal represents the algebraic sum...

Cardiac Monitoring31 Jan 2026
ANZCA Primary
Equipment-Physics
High evidence
ANZCA Primary Written
+1
ANZCA

ECMO Cannulation and Vascular Access

Extracorporeal membrane oxygenation (ECMO) cannulation establishes vascular access for temporary mechanical circulatory and/or respiratory support. Two configurations exist: (1) Veno-arterial (VA) - femoral vein...

Mechanical Circulatory Support3 Feb 2026
Anaesthesia
Cardiothoracic Surgery
A evidence
ANZCA Final Examination
+1
ANZCA

Electrical Injury and Lightning Strike

Electrical injuries cause devastating deep tissue damage, cardiac arrhythmias, and systemic complications disproportionate to visible burns. Key principles:

Environmental Emergencies3 Feb 2026
ANZCA Final
Trauma Anaesthesia
A evidence
ANZCA Final Written
+3
ANZCA

Electroconvulsive Therapy (ECT) Anaesthesia

Electroconvulsive therapy (ECT) involves inducing a generalized tonic-clonic seizure under general anaesthesia for treatment of severe psychiatric disorders. Anaesthetic goals : Provide brief unconsciousness (2-5...

Special Procedures3 Feb 2026
ANZCA Final
Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

End-of-Life Care in Anaesthesia

Comprehensive guide to palliative care, organ donation in Australia/NZ, and withholding/withdrawing treatment for ANZCA Fellowship examination Professional Skills component

Professional Skills
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Ephedrine Pharmacology

Ephedrine is a non-catecholamine sympathomimetic amine with both direct and indirect actions at alpha and beta adrenergic receptors. It is a naturally occurring alkaloid found in plants of the Ephedra species....

Mixed-acting Sympathomimetics3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+2
ANZCA

Epidural Anaesthesia

Epidural anaesthesia involves injection of local anaesthetic into the epidural space (potential space between ligamentum flavum and dura) producing segmental sensory block with less motor block than spinal. Anatomy:...

Regional Techniques2 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Epilepsy Surgery and Awake Craniotomy

Epilepsy surgery requires seamless transitions between general anaesthesia (GA), conscious sedation, and awake cooperative states to enable intraoperative electrocorticography (ECoG) and functional cortical mapping....

Functional Neurosurgery3 Feb 2026
ANZCA Final
Neuroanaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Erector Spinae Plane Block

Composition: The erector spinae is a large, complex muscle group located posterior to the vertebral column, consisting of three columns:

Fascial Plane Blocks3 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+3
ANZCA

Ethics, Consent, and Capacity in Anaesthesia

Comprehensive guide to informed consent, capacity assessment, advance directives, and refusal of treatment for ANZCA Fellowship examination Professional Skills component

Professional Skills
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Etomidate Pharmacology

Etomidate is an imidazole-derived intravenous anaesthetic agent distinguished by its remarkable haemodynamic stability, making it the induction agent of choice for patients with cardiovascular compromise or...

Intravenous Anaesthetic Agents31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Evidence-Based Medicine and Research in Anaesthesia

Evidence-based medicine (EBM) integrates individual clinical expertise with the best available external clinical evidence from systematic research. Hierarchy of evidence : Systematic reviews and meta-analyses of RCTs...

General2 Feb 2026
ANZCA Final
Research Methods
High evidence
ANZCA Final Written
+1
ANZCA

Extracorporeal Membrane Oxygenation (ECMO): VV and VA Configurations, Cannulation, and Management

Extracorporeal Membrane Oxygenation (ECMO) provides temporary cardiopulmonary support by draining venous blood, removing carbon dioxide and adding oxygen through a membrane oxygenator, and returning oxygenated blood...

Mechanical Circulatory Support3 Feb 2026
ANZCA Primary
Equipment
High evidence
ANZCA Primary Written
+2
ANZCA

Failed Spinal Anaesthesia: Management Options and Intubation Strategy

Failed spinal anaesthesia occurs in 1-5% of caesarean sections , with complete failure reported in 0.5-1% of cases. When spinal anaesthesia fails to provide adequate surgical anaesthesia, the anaesthetist must rapidly...

3 Feb 2026
ANZCA Final
Obstetric Anaesthesia
+2
ANZCA

Femoral Nerve Block

Origin and Course: Formed from : L2-L4 lumbar plexus (posterior divisions) Exits : Lateral border psoas muscle Passes : Beneath inguinal ligament Position : Lateral to femoral artery, deep to fascia iliaca,...

Regional2 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Fentanyl

Fentanyl is a synthetic phenylpiperidine opioid agonist with 100× potency of morphine and rapid onset (1-2 minutes IV), making it ideal for intraoperative analgesia and balanced anaesthesia. Mechanism: Selective...

Opioid Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Fluid and Electrolyte Physiology

Total body water (TBW) is approximately 60% body weight in males, 50% in females, 65-70% in infants, 50% in elderly. Distribution : 2/3 intracellular (ICF), 1/3 extracellular (ECF). ECF divided into interstitial fluid...

Physiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Flumazenil Pharmacology

Flumazenil is a competitive benzodiazepine antagonist at the GABA-A receptor benzodiazepine binding site. Chemically classified as an imidazobenzodiazepine, it reverses the sedative, anxiolytic, and amnestic effects...

GABA-A Receptor Modulators1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Foreign Body Aspiration - Acute Upper Airway Obstruction and Bronchoscopy

Foreign body aspiration is the inhalation of objects into the airway, most commonly affecting children aged 1-3 years (peak incidence). It is a life-threatening emergency requiring prompt diagnosis and intervention....

Paediatric Emergency3 Feb 2026
ANZCA Final
Paediatric Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Gabapentinoids Pharmacology (Gabapentin and Pregabalin)

Gabapentinoids (gabapentin and pregabalin) are anticonvulsant medications that bind to the α2δ subunit of voltage-gated calcium channels (VGCCs) , reducing presynaptic calcium influx and neurotransmitter release...

Adjuvant Analgesics1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Gas Laws in Anaesthesia - Boyle's, Charles', Dalton's, Henry's, Graham's, Fick's

Gas laws form the foundation of respiratory physiology and anaesthetic practice. Boyle's law (P₁V₁ = P₂V₂) describes the inverse relationship between pressure and volume at constant temperature, governing lung...

Physics31 Jan 2026
ANZCA Primary
Equipment-Physics
High evidence
ANZCA Primary Written
+1
ANZCA

General Anaesthesia Induction

General anaesthesia induction is the transition from consciousness to unconsciousness with loss of protective airway reflexes, requiring controlled manipulation of physiology and airway management. Rapid sequence...

General Clinical2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Glyceryl Trinitrate (GTN) Pharmacology

Glyceryl trinitrate (GTN), also known as nitroglycerin, is an organic nitrate vasodilator that has been used clinically for over 150 years for the treatment of angina pectoris and heart failure. It is a triester of...

Nitrate Vasodilators3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+2
ANZCA

Glycopyrrolate

Glycopyrrolate is a quaternary ammonium anticholinergic agent with peripheral muscarinic receptor antagonism, used primarily to counteract muscarinic side effects of anticholinesterases during neuromuscular blockade...

Anticholinergics2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Glycopyrrolate Pharmacology

Glycopyrrolate (glycopyrronium bromide) is a synthetic quaternary ammonium anticholinergic agent that acts as a competitive muscarinic receptor antagonist at M1, M2, and M3 receptor subtypes. Its quaternary ammonium...

Muscarinic Antagonists31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Haemodynamics: Blood Flow, Pressure, and Resistance

Haemodynamics describes blood flow through the cardiovascular system based on pressure gradients and vascular resistance. Poiseuille's Law: Q = ΔP × πr⁴ / (8ηL), where Q = flow, ΔP = pressure gradient, r = vessel...

Cardiovascular Physiology31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Hepatic Physiology

The liver is the largest solid organ (1.5 kg) performing over 500 functions including metabolism, detoxification, protein synthesis, and bile production. Blood supply: Dual supply from hepatic artery (25% flow, 50%...

Organ Physiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

High Spinal and Total Spinal Block - Recognition and Management

Immediate Recognition: Sensory level above T4 (high spinal) with respiratory symptoms Progressive ascending weakness (numbness in hands T1-T4, respiratory C3-C5) Severe hypotension with bradycardia (sympathetic...

Anaesthetic Crisis Management3 Feb 2026
Anaesthesia
ANZCA Final
A - Evidence-Based Guidelines evidence
ANZCA Final Written
ANZCA

Hydralazine: Direct Vasodilator Pharmacology and Clinical Use

Hydralazine is a direct-acting arterial vasodilator that relaxes vascular smooth muscle through unclear mechanisms, possibly involving interference with calcium influx and activation of potassium channels. It produces...

3 Feb 2026
ANZCA Primary
Pharmacology
+1
ANZCA

Hyperthermia and Heat Stroke

Heat stroke is a life-threatening hyperthermic emergency with core temperature 40°C and neurological dysfunction. Rapid cooling is the priority. Key principles:

Environmental Emergencies3 Feb 2026
ANZCA Final
Emergency Medicine
A evidence
ANZCA Final Written
+2
ANZCA

Hypertrophic Cardiomyopathy - Anaesthetic Considerations

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder (1:500 population), characterised by asymmetric left ventricular hypertrophy with myocardial disarray, presenting significant anaesthetic...

3 Feb 2026
anaesthesia
cardiothoracic-anaesthesia
ANZCA Final Written
ANZCA

Interscalene Brachial Plexus Block

Formation: Roots : C5, C6, C7, C8, T1 (ventral rami) Interscalene location : C5-C7 roots between anterior and middle scalene muscles Trunks : Form superior (C5-C6), middle (C7), inferior (C8-T1) trunks Interscalene...

Regional2 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Interventional Pain Procedures

Interventional pain procedures provide diagnostic information and therapeutic benefit for chronic pain conditions when conservative management fails. Epidural steroid injection (ESI): Indicated for radicular pain from...

Pain Medicine2 Feb 2026
ANZCA Final
Pain Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Intra-Aortic Balloon Pump (IABP): Physiology, Timing, and Clinical Applications

The intra-aortic balloon pump (IABP) is a mechanical circulatory support device that improves myocardial oxygen supply-demand balance through diastolic augmentation and systolic unloading (counterpulsation). The...

Mechanical Circulatory Support3 Feb 2026
ANZCA Primary
Equipment
High evidence
ANZCA Primary Written
+1
ANZCA

Intracranial Pressure Management

Intracranial pressure (ICP) is normally 5-15 mmHg (supine). Cerebral perfusion pressure (CPP) = MAP - ICP (target 60-70 mmHg). Monro-Kellie doctrine : Fixed intracranial volume (brain 80%, CSF 10%, blood 10%). ICP...

Neurosurgical2 Feb 2026
ANZCA Final
Neurosurgery
High evidence
ANZCA Final Written
+1
ANZCA

Intraoperative Bronchospasm - Recognition and Management

Immediate Recognition: Rising peak airway pressure ( 30 cmH₂O with plateau pressure unchanged suggests bronchospasm) Expiratory wheeze (may be absent in severe bronchospasm = "silent chest") Decreased tidal volume...

Anaesthetic Crisis Management3 Feb 2026
Anaesthesia
ANZCA Final
A - Evidence-Based Guidelines evidence
ANZCA Final Written
ANZCA

Isoflurane Pharmacology

Isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) is a halogenated methyl ethyl ether volatile anaesthetic agent introduced in 1981 that remains widely used globally for maintenance of general...

Volatile Agents1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Ketamine

Ketamine is a phencyclidine (PCP) derivative dissociative anaesthetic producing analgesia, amnesia, and unconsciousness while preserving airway reflexes and cardiovascular stability. Mechanism: Non-competitive...

IV Anaesthetics2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Ketamine Pharmacology

Ketamine is a phencyclidine derivative dissociative anaesthetic that exists as two stereoisomers: S(+)-ketamine and R(-)-ketamine. The S(+)-enantiomer demonstrates 3-4 times greater analgesic potency and 1.5-2 times...

Intravenous Anaesthetic Agents31 Jan 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Labour Analgesia

Cervical Dilation and Uterine Contractions (0-10 cm): Origin: Uterine contractions, cervical dilation, lower uterine segment distension Pathway: Visceral afferents via hypogastric plexus → sympathetic chain → enter...

Obstetric Anaesthesia2 Feb 2026
ANZCA Final
Obstetric Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Lignocaine (Lidocaine)

Lignocaine (lidocaine) is the prototypical amide local anaesthetic, widely used for infiltration, nerve blocks, spinal and epidural anaesthesia, intravenous regional anaesthesia (Bier's block), and as an...

Local Anaesthetic Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Local Anaesthetic Systemic Toxicity (LAST)

Local anaesthetic systemic toxicity (LAST) is a life-threatening emergency occurring when local anaesthetics enter systemic circulation, causing CNS and cardiovascular toxicity. Incidence: 0.1-0.3% of peripheral nerve...

Crisis Management2 Feb 2026
ANZCA Final
Resuscitation
High evidence
ANZCA Final Written
+1
ANZCA

Local Anaesthetic Systemic Toxicity (LAST) - Management and Lipid Emulsion

Immediate Recognition (Early Warning Signs): Prodromal symptoms: Circumoral numbness, metallic taste, tinnitus Neurological: Agitation, confusion, drowsiness, seizures Cardiovascular: Hypertension, tachycardia...

Anaesthetic Crisis Management3 Feb 2026
Anaesthesia
ANZCA Final
A - Evidence-Based Guidelines evidence
ANZCA Final Written
ANZCA

Local Anaesthetics

Local anaesthetics (LAs) block nerve conduction by inhibiting voltage-gated sodium channels (VGSC) in neuronal membranes, preventing action potential generation and propagation. Classification: Esters (procaine,...

Local Anaesthetic Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Lower Limb Nerve Blocks

The lumbar plexus forms within the psoas major muscle from the anterior rami of L1-L4 nerve roots. It gives rise to several important branches that innervate the anterior and medial thigh:

Regional Anaesthesia31 Jan 2025
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Magnesium Pharmacology

Magnesium (Mg²⁺) is the fourth most abundant cation in the body and second most abundant intracellular cation, with critical roles in over 300 enzymatic reactions, neuromuscular transmission, and cardiac...

Electrolytes/Minerals1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Malignant Hyperthermia: Recognition and Management

Malignant hyperthermia (MH) is a pharmacogenetic disorder triggered by volatile anaesthetics (sevoflurane, isoflurane, desflurane, halothane) and suxamethonium . Pathophysiology : Ryanodine receptor (RYR1) or DHPR...

Resuscitation-Critical2 Feb 2026
ANZCA Final
Crisis Management
High evidence
ANZCA Final Written
+1
ANZCA

Massive Haemorrhage and Transfusion

Massive haemorrhage is defined as loss of 50% total blood volume within 3 hours, or blood loss exceeding 150 mL/min. Mortality ranges from 30-40% for trauma-related massive transfusion and 10-20% for surgical...

Resuscitation and Critical Incidents2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+2
ANZCA

Massive Transfusion Protocol (MTP) - Hemorrhage Management

Activation Criteria (Activate MTP if ANY present): Blood loss 1500 mL or 30% blood volume Blood loss 150 mL/min sustained Need for 4 units PRBC in <1 hour Systolic BP <90 mmHg with ongoing bleeding Base deficit...

Anaesthetic Crisis Management3 Feb 2026
Anaesthesia
ANZCA Final
A - Evidence-Based Guidelines evidence
ANZCA Final Written
ANZCA

Maternal Physiological Changes in Pregnancy

Pregnancy induces profound physiological adaptations that significantly impact anaesthetic management. By term, cardiac output increases 40-50% (stroke volume +30%, heart rate +15-20%), blood volume expands 40-50%...

Obstetric Anaesthesia31 Jan 2025
ANZCA Final
Obstetric Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Maze Procedure and Atrial Fibrillation Ablation

The Maze procedure is a surgical treatment for atrial fibrillation (AF) that creates lines of conduction block in the atrial myocardium to restore sinus rhythm. Modern techniques include cut-and-sew Cox-Maze III/IV,...

Cardiac Surgery3 Feb 2026
Anaesthesia
Cardiothoracic Surgery
A evidence
ANZCA Final Examination
ANZCA

Mechanical Ventilators

Pneumatic (Gas-Powered): Driven entirely by compressed gas (oxygen or air at 280-600 kPa) No electrical power required for basic function Examples: Ohmeda 7000, Penlon Nuffield 200 Advantages: Simple, reliable,...

Anaesthetic Equipment1 Feb 2025
ANZCA Primary
Equipment
Moderate evidence
ANZCA Primary Written
+1
ANZCA

Mechanical Ventilators

Mechanical ventilators provide controlled ventilation during general anaesthesia or in critical care settings. Classification: Pneumatic (gas-driven, no electricity required, simple), electronic...

Anaesthetic Equipment2 Feb 2026
ANZCA Primary
Equipment
High evidence
ANZCA Primary Written
+1
ANZCA

Medical Ultrasound Physics: Knobology, Artifacts, and Doppler Principles

Medical ultrasound imaging relies on the piezoelectric effect —certain crystals (lead zirconate titanate, PZT) convert electrical energy to mechanical sound waves and vice versa. Image generation follows:...

Ultrasound Physics and Equipment3 Feb 2026
ANZCA Primary
Equipment-Physics
High evidence
ANZCA Primary Written
+1
ANZCA

Medicolegal Issues in Anaesthesia

Comprehensive guide to medical negligence, duty of care, documentation requirements, and expert witness responsibilities for ANZCA Fellowship examination Professional Skills component

Professional Skills
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Metaraminol Pharmacology

Metaraminol is a synthetic sympathomimetic amine used primarily as a vasopressor for the management of intraoperative hypotension, particularly during spinal anaesthesia for caesarean section. It acts through both...

Sympathomimetics31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Midazolam Pharmacology

Midazolam is a water-soluble imidazobenzodiazepine that acts as a positive allosteric modulator of GABA-A receptors at the alpha-gamma subunit interface, enhancing chloride conductance to produce anxiolysis, amnesia,...

Sedatives/Hypnotics1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Midazolam: Pharmacology and Clinical Use

Midazolam is a short-acting benzodiazepine with anxiolytic, amnestic, sedative-hypnotic, and muscle relaxant properties. Mechanism : Positive allosteric modulation of GABA-A receptors (increases chloride conductance,...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
ANZCA

Morphine

Morphine is the prototypical phenanthrene μ-opioid receptor (MOR) agonist, the gold standard against which other opioids are compared. Structure: Phenanthrene backbone (5-ring structure), tertiary amine, two hydroxyl...

Opioid Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Morphine Pharmacology

Morphine is the prototypical natural opioid analgesic derived from the phenanthrene alkaloid class, acting as a full agonist at mu (μ), kappa (κ), and delta (δ) opioid receptors with primary clinical effects mediated...

Analgesic Pharmacology1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Motor Evoked Potentials in Anaesthesia

Motor evoked potentials (MEPs) monitor corticospinal tract integrity during surgeries risking spinal cord or brain motor pathway injury. Indications : Spinal deformity correction (scoliosis), spinal cord tumor...

Neurosurgical3 Feb 2026
ANZCA Final
Neurosurgery
High evidence
ANZCA Final Written
+2
ANZCA

Multiple Gestation and Anaesthesia

Multiple gestations (twins, triplets, higher-order multiples) complicate 1.6% of pregnancies in Australia but account for 10-15% of perinatal mortality and morbidity. Twin pregnancies are classified as monochorionic...

High-Risk Obstetrics3 Feb 2026
ANZCA Final
Obstetric Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Near-Drowning and Submersion Injury

Near-drowning (submersion with survival 24 hours) causes severe hypoxic brain injury, pulmonary complications, and often hypothermia. Key principles:

Environmental Emergencies3 Feb 2026
ANZCA Final
Trauma Anaesthesia
A evidence
ANZCA Final Written
+2
ANZCA

Neonatal Anaesthesia

Fetal circulation physiology - PVR SVR, PDA-dependent lesions, transition challenges Immature organ systems - Low lung compliance, immature cardiac calcium handling, impaired thermoregulation Pharmacokinetic...

Neonatal3 Feb 2026
ANZCA Final
Paediatric Anaesthesia
A evidence
ANZCA Final Written
ANZCA

Neostigmine

Neostigmine is a reversible acetylcholinesterase inhibitor used to reverse non-depolarizing neuromuscular blockade (NMB) by increasing acetylcholine (ACh) concentration at the neuromuscular junction, overcoming...

Anticholinesterases2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Neostigmine and Anticholinesterase Pharmacology

Neostigmine is a quaternary ammonium anticholinesterase agent that reversibly inhibits acetylcholinesterase through carbamylation, increasing acetylcholine concentration at the neuromuscular junction to reverse...

Autonomic Pharmacology1 Feb 2026
ANZCA Primary
Pharmacology
A evidence
ANZCA Primary Examination
+1
ANZCA

Neuraxial Anaesthesia in Obstetrics

What is it? Neuraxial anaesthesia encompasses epidural, spinal, and combined spinal-epidural (CSE) techniques for labour analgesia and caesarean delivery. These techniques provide superior pain relief with minimal...

Obstetric Anaesthesia3 Feb 2026
Anaesthesia
Obstetrics
A evidence
+1
ANZCA

Neuromuscular Junction Physiology

Neuromuscular junction (NMJ) is cholinergic synapse between motor neuron and skeletal muscle. Motor neuron action potential → voltage-gated Ca²⁺ channels open → Ca²⁺ influx → ACh vesicle exocytosis (quantal release)....

Neuromuscular Physiology31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Neuromuscular Monitoring

Concept Key Facts --------- ----------- Supramaximal stimulation Current 20-25% above maximal response; ensures all motor fibres activated Electrode placement Ulnar nerve at wrist (adductor pollicis); cathode distal...

Clinical Monitoring1 Feb 2025
ANZCA Primary
Equipment
High evidence
ANZCA Primary Written
+1
ANZCA

Neuropathic Pain - Mechanisms and Management

Neuropathic pain is defined by the International Association for the Study of Pain (IASP) as "pain caused by a lesion or disease of the somatosensory nervous system." It affects 6-10% of the general population, with...

Chronic Pain3 Feb 2026
ANZCA Final
Pain Medicine
A evidence
ANZCA Final Written
+1
ANZCA

Neurophysiological Monitoring

Intraoperative neurophysiological monitoring (IONM) detects neurological injury during surgery allowing prompt intervention to prevent permanent damage. SSEP (Somatosensory Evoked Potentials): Stimulation of...

Neurosurgical2 Feb 2026
ANZCA Final
Neuroanaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Neurophysiology for Anaesthesia

Cerebral blood flow (CBF) is normally 50 mL/100g/min (15% cardiac output). Cerebral metabolic rate for oxygen (CMRO₂) : 3.5 mL/100g/min. Cerebral perfusion pressure (CPP) = MAP - ICP (or CVP, whichever higher), normal...

Physiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Neurostimulation & Ultrasound in Regional Anaesthesia

Neurostimulation and ultrasound guidance have transformed regional anaesthesia by improving block success rates and reducing complications. Ultrasound provides real-time visualization of nerves, needle trajectory, and...

Regional Anaesthesia31 Jan 2025
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Nitrous Oxide Pharmacology

Nitrous oxide (N2O) is a colourless, sweet-smelling inhalational anaesthetic agent with unique physicochemical properties that distinguish it from volatile anaesthetics. Key ANZCA Primary exam points include:...

General Anaesthesia1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Nitrous Oxide Pharmacology

Nitrous oxide (N2O) is a colorless, odorless, non-irritating gas and the only inorganic compound used as a general anaesthetic. It is the weakest inhalational anaesthetic with a MAC (minimum alveolar concentration) of...

Inhalational Anaesthetic Agents3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Non-Invasive Blood Pressure Monitoring

Non-invasive blood pressure (NIBP) monitoring is a fundamental monitoring modality in anaesthesia, with the oscillometric method being the most widely used automated technique. An inflatable cuff occludes arterial...

Cardiovascular Monitoring31 Jan 2026
ANZCA Primary
Equipment-Physics
High evidence
ANZCA Primary Written
+1
ANZCA

Noradrenaline (Norepinephrine) Pharmacology

Noradrenaline (norepinephrine) is an endogenous catecholamine and the primary neurotransmitter of the sympathetic nervous system, acting predominantly at alpha-1 adrenoceptors (potent vasoconstriction) with additional...

Cardiovascular Pharmacology1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Obstetric Haemorrhage - PPH and Massive Transfusion

Primary PPH is defined as blood loss ≥500 mL within 24 hours of vaginal delivery or ≥1000 mL following cesarean section. Major PPH is blood loss 1000 mL or blood loss accompanied by signs of hypovolemia. PPH affects...

Obstetric Emergencies3 Feb 2026
ANZCA Final
Obstetric Anaesthesia
A evidence
ANZCA Final Written
+2
ANZCA

Ondansetron Pharmacology

Ondansetron is a selective 5-HT₃ (serotonin type 3) receptor antagonist used primarily for the prevention and treatment of postoperative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV)....

5-HT3 Receptor Antagonists31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Oxycodone and Tramadol Pharmacology

Oxycodone and tramadol represent two distinct approaches to opioid analgesia with fundamentally different pharmacological profiles essential for ANZCA Primary examination. Oxycodone is a semi-synthetic opioid derived...

Opioids1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Oxygen Delivery Systems

Oxygen delivery systems provide supplemental oxygen to patients with varying degrees of efficiency and control. Variable performance devices (nasal cannula, simple mask): Delivered FiO2 depends on patient's...

Anaesthetic Equipment2 Feb 2026
ANZCA Primary
Equipment
High evidence
ANZCA Primary Written
+1
ANZCA

Oxygen Transport & Haemoglobin Dissociation Curve

Oxygen transport from lungs to tissues occurs via two mechanisms: physically dissolved in plasma (3%) and chemically bound to hemoglobin (97%). Each gram of hemoglobin can bind approximately 1.34 mL of oxygen, giving...

Respiratory Physiology31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Paediatric Airway Anatomy & Physiology

Paediatric airway management requires understanding of profound anatomical and physiological differences from adults. Infants have a proportionally larger occiput, larger tongue, higher larynx (C3-C4), and...

Paediatric Anaesthesia31 Jan 2026
ANZCA Final
Paediatric Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Paediatric Anaesthesia Principles

Paediatric anaesthesia requires understanding of age-related physiological differences . Airway : Large tongue, cephalad larynx (C3-4 vs C4-5 in adults), narrow cricoid (subglottic region), short trachea, prominent...

Paediatric2 Feb 2026
ANZCA Final
Paediatric Anaesthesia
High evidence
ANZCA Final Written
ANZCA

Paediatric Cardiac Anaesthesia

Understanding circulation patterns - Systemic vs pulmonary blood flow balance, Qp:Qs ratios Shunt physiology - Direction and magnitude affect oxygenation and cardiac output Single ventricle physiology - Series...

Congenital Heart Disease3 Feb 2026
ANZCA Final
Paediatric Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Paediatric Trauma

Blood volume - 80 mL/kg (neonate) to 70 mL/kg (older child); hypovolaemic shock manifests late TBI management - Age-specific GCS, higher tolerance for hypotension but avoid hypoxia at all costs Hypotensive...

Emergency Anaesthesia3 Feb 2026
ANZCA Final
Paediatric Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Pain Pathways & Transmission (Gate Control Theory)

Pain transmission involves first-order neurons (Aδ myelinated, 5-30 m/s, sharp/fast pain; C unmyelinated, 0.5-2 m/s, dull/slow pain) from peripheral nociceptors → dorsal horn (substantia gelatinosa, Rexed laminae I,...

Pain Physiology31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+2
ANZCA

Paravertebral Block

Medial: Vertebral body (posterior aspect) Intervertebral disc Intervertebral foramen Lateral border of vertebral canal

Neuraxial Techniques3 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+3
ANZCA

Pelvic Fracture: Haemorrhage Control and Anaesthetic Management

Pelvic fractures in trauma are associated with life-threatening haemorrhage due to disruption of the extensive pelvic venous plexus and arterial network. Immediate haemorrhage control involves application of a pelvic...

3 Feb 2026
ANZCA Final
Trauma
+1
ANZCA

Pericardiectomy for Constrictive Pericarditis

Pericardiectomy is the surgical removal of the pericardium for constrictive pericarditis, a condition where a thickened, fibrotic, or calcified pericardium restricts diastolic filling, creating a "stiff shell" around...

Cardiac Surgery3 Feb 2026
Anaesthesia
Cardiothoracic Surgery
A evidence
ANZCA Final Examination
ANZCA

Perioperative Anaemia Management

Comprehensive guide to patient blood management, iron deficiency, EPO, and transfusion triggers for ANZCA Fellowship examination

Perioperative Medicine
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Perioperative Anaphylaxis

Anaphylaxis is an acute, potentially life-threatening systemic hypersensitivity reaction mediated by immunological (IgE or IgG) or non-immunological mechanisms. In the perioperative setting, IgE-mediated (Type I)...

Resuscitation and Critical Incidents2 Feb 2026
ANZCA Final
Resuscitation
High evidence
ANZCA Final Written
+2
ANZCA

Perioperative Anaphylaxis: Recognition, Adrenaline Dosing, and Refractory Management

Perioperative anaphylaxis is a severe, life-threatening systemic hypersensitivity reaction occurring during or immediately after anaesthesia, with an estimated incidence of 1 in 10,000 to 1 in 20,000 anaesthetics....

3 Feb 2026
ANZCA Final
Crisis Management
+1
ANZCA

Perioperative Arrhythmia Management

Comprehensive guide to atrial fibrillation management, beta-blockers, amiodarone, and perioperative cardiac rhythm disturbances for ANZCA Fellowship examination

Perioperative Medicine
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Perioperative Aspiration: Mendelson Syndrome, Rapid Sequence Induction, and Cricoid Pressure

Perioperative pulmonary aspiration occurs in 1 in 3,000 to 1 in 6,000 general anaesthetics , with significant aspiration (leading to respiratory compromise) in approximately 1 in 10,000 . Mendelson syndrome —the...

3 Feb 2026
ANZCA Final
Crisis Management
+1
ANZCA

Perioperative Cardiac Arrest

Hypoxaemia (25-30% of cases): Inadequate airway: Difficult intubation, CICV scenario, airway obstruction Ventilation failure: Equipment malfunction, circuit disconnection, esophageal intubation Pulmonary pathology:...

Resuscitation and Critical Incidents2 Feb 2026
ANZCA Final
Resuscitation
High evidence
ANZCA Final Written
+2
ANZCA

Perioperative Diabetes Management

Diabetes mellitus affects 5-10% of Australian surgical patients, with perioperative hyperglycaemia associated with increased wound infections (30% higher), mortality, and hospital length of stay. Preoperative...

General Clinical2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Perioperative Diabetes Management: Glycemic Control, Insulin Protocols, and Hypoglycemia Prevention

Diabetes mellitus affects 10-15% of surgical patients , with perioperative hyperglycemia associated with increased morbidity including surgical site infections, delayed wound healing, cardiovascular events, and...

3 Feb 2026
ANZCA Final
Perioperative Medicine
+2
ANZCA

Perioperative Medicine and Optimisation

Comprehensive guide to perioperative optimisation, comorbidity management, and multidisciplinary care pathways for ANZCA Fellowship examination

Perioperative Medicine
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Perioperative Temperature Management

Comprehensive guide to thermoregulation physiology, hypothermia prevention, temperature monitoring, and therapeutic temperature management for ANZCA Fellowship examination

Perioperative Medicine
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Pharmacodynamics

The concept of receptors as specific drug recognition sites originated with Langley (1878) and Ehrlich (1900), establishing that drugs exert effects by interacting with discrete molecular targets rather than through...

Drug-Receptor Interactions and Mechanisms of Action1 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Pharmacokinetics

The relevance of pharmacokinetics to anaesthesia is profound. Intravenous anesthetics, opioids, neuromuscular blocking agents, and vasoactive drugs all exhibit complex pharmacokinetic profiles that influence onset...

Drug Absorption, Distribution, Metabolism, and Elimination1 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Phenylephrine Pharmacology

Phenylephrine is a synthetic, non-catecholamine sympathomimetic amine that acts as a selective alpha-1 adrenergic receptor agonist with minimal beta-adrenergic activity. Unlike catecholamines (epinephrine,...

Cardiovascular Pharmacology31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Phenylephrine: Pharmacology and Clinical Use

Phenylephrine is a direct-acting α-1 adrenergic receptor agonist with potent vasoconstrictor effects and no β-activity. Mechanism : Stimulates postsynaptic α-1 receptors on vascular smooth muscle → vasoconstriction →...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Pituitary Surgery and Transsphenoidal Hypophysectomy

Transsphenoidal pituitary surgery requires managing endocrine dysfunction, fluid balance, and unique surgical positioning. Key principles:

Skull Base Surgery3 Feb 2026
ANZCA Final
Neuroanaesthesia
A evidence
ANZCA Final Written
+2
ANZCA

Popliteal Sciatic Nerve Block

The popliteal fossa is a diamond-shaped space posterior to the knee joint containing the neurovascular structures supplying the lower leg and foot.

Lower Limb Regional3 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Postoperative Nausea and Vomiting Prophylaxis

Postoperative nausea and vomiting (PONV) affects 20-30% of surgical patients and 70-80% of high-risk patients, significantly impacting patient satisfaction, delaying discharge, and increasing costs. Risk...

General Clinical2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Postoperative Pain Management

Somatic Pain: Tissue injury from surgical incision and manipulation Mediators: Bradykinin, histamine, prostaglandins, substance P, serotonins Receptors: Aδ and C fibers (Aδ: sharp, localized; C: dull, aching)...

Acute Pain Medicine2 Feb 2026
ANZCA Final
Pain Medicine
High evidence
ANZCA Final Written
+1
ANZCA

Pre-eclampsia and Anaesthesia

Pre-eclampsia affects 3-5% of pregnancies in Australia and is a leading cause of maternal morbidity and mortality, with higher incidence in Aboriginal and Torres Strait Islander women (5-8%). It is defined as...

Obstetric Anaesthesia2 Feb 2026
ANZCA Final
Obstetric Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Pre-operative Assessment for Cardiac Surgery

Cardiac surgery represents one of the most extensively studied surgical specialties, with robust outcome data:

Cardiothoracic Anaesthesia31 Jan 2025
ANZCA Final
Cardiothoracic Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Pre-operative Cardiovascular Assessment

Perioperative cardiac stress results from sympathetic activation, fluid shifts, pain, and inflammation. Surgical stress increases myocardial oxygen demand while simultaneously compromising supply through tachycardia...

Preoperative Assessment31 Jan 2025
ANZCA Final
Clinical Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Preoperative Cardiac Risk Assessment

Comprehensive guide to cardiac risk stratification including RCRI, functional capacity assessment, and preoperative testing for ANZCA Fellowship examination

Perioperative Medicine
Anaesthesia
A evidence
ANZCA Final Examination
ANZCA

Pressure Transducers & Invasive Monitoring

Pressure transducers convert mechanical pressure into electrical signals for continuous hemodynamic monitoring. Modern disposable transducers use piezoresistive strain gauges arranged in a Wheatstone bridge circuit ,...

Measurement Systems31 Jan 2026
ANZCA Primary
Equipment-Physics
High evidence
ANZCA Primary Written
+1
ANZCA

Prone Positioning for Surgery

Prone positioning is essential for posterior spinal, neurosurgical, and some plastic/ENT procedures. Physiological effects : Reduced cardiac output (10-20% decrease), increased central venous pressure, decreased...

Surgical Positioning3 Feb 2026
ANZCA Final
Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Propofol

Propofol (2,6-diisopropylphenol) is the most commonly used intravenous anaesthetic agent for induction and maintenance of general anaesthesia and sedation in ICU. Structure: Simple phenol derivative with two isopropyl...

IV Anaesthetics2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Propofol Pharmacology

Propofol (2,6-diisopropylphenol) is a phenol derivative intravenous anaesthetic that acts primarily as a positive allosteric modulator of GABA A receptors, particularly at the beta-subunit, increasing chloride...

Intravenous Anaesthetic Agents31 Jan 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Pulmonary Gas Exchange

Gas exchange between alveolar air and pulmonary capillary blood occurs through passive diffusion across the alveolar-capillary membrane driven by partial pressure gradients. The alveolar-capillary membrane consists of...

Respiratory Physiology31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Pulse Oximetry

Core Physics: Two wavelengths : Red (660 nm) absorbed more by deoxyhemoglobin (Hb); Infrared (940 nm) absorbed more by oxyhemoglobin (HbO2) Ratio of Ratios (R) : R = (AC/DC)660 / (AC/DC)940, empirically calibrated to...

Non-Invasive Monitoring31 Jan 2026
ANZCA Primary
Equipment-Physics
High evidence
ANZCA Primary Written
+1
ANZCA

Pyloric Stenosis

Hypertrophic pyloric stenosis is a condition of acquired gastric outlet obstruction caused by hypertrophy of the pyloric muscle, typically presenting at 3-8 weeks of life with projectile vomiting. Key anaesthetic...

Gastrointestinal3 Feb 2026
ANZCA Final
Paediatric Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Quadratus Lumborum Block

Structure: The quadratus lumborum (QL) is a thick, quadrilateral muscle located in the posterior abdominal wall, extending between the 12th rib and the iliac crest.

Fascial Plane Blocks3 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+3
ANZCA

Quality and Safety in Anaesthesia

Patient safety is a core competency for anaesthetists. Human factors : Understanding how humans interact with systems, equipment, and each other; human error inevitable, systems must be designed to prevent or catch...

General2 Feb 2026
ANZCA Final
Quality Improvement
High evidence
ANZCA Final Written
+1
ANZCA

Rectus Sheath Block

Formation: The rectus sheath is a fibrous compartment formed by the aponeuroses of the three lateral abdominal wall muscles (external oblique, internal oblique, transversus abdominis) as they envelop the rectus...

Truncal Blocks3 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Remifentanil Pharmacology

Remifentanil is a synthetic ultra-short-acting mu-opioid agonist distinguished by its unique ester linkage that allows rapid hydrolysis by non-specific tissue and plasma esterases, resulting in organ-independent...

Intravenous Opioid Analgesics31 Jan 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Renal Physiology

The kidneys maintain homeostasis through filtration, reabsorption, secretion, and excretion, processing 180 L/day of glomerular filtrate to produce 1-2 L urine. Renal blood flow: 20-25% cardiac output (1.0-1.2 L/min),...

Organ Physiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Research Methodology, Statistics and Critical Appraisal

Hierarchy of Evidence: Systematic reviews/Meta-analyses (highest) Randomised Controlled Trials (RCTs) Cohort studies Case-control studies Case series/Case reports Expert opinion (lowest)

Professional Skills3 Feb 2026
Anaesthesia
ANZCA Final
A - Evidence-Based Guidelines evidence
ANZCA Final Written
ANZCA

Respiratory Mechanics

The respiratory system functions as a pump that moves gas between the atmosphere and alveoli through cyclical changes in thoracic volume. Respiratory mechanics characterizes this pump's performance through three...

Respiratory Physiology31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Respiratory Physiology

The respiratory system maintains gas exchange through ventilation, diffusion, and perfusion, tightly regulated to maintain PaO₂ 80-100 mmHg and PaCO₂ 35-45 mmHg. Ventilation: Tidal volume (500 mL) × respiratory rate...

Organ Physiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Retinoblastoma - Ocular Oncology and Intra-Arterial Chemotherapy

Retinoblastoma is the most common primary intraocular malignancy in children , with an incidence of 1 in 15,000-20,000 live births (approximately 300 new cases per year in the USA, 8-10 per year in Australia). It is...

Paediatric Oncology3 Feb 2026
ANZCA Final
Paediatric Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Robotic Surgery Anaesthesia

Robotic-assisted surgery (RAS) presents unique anaesthetic challenges due to the combination of pneumoperitoneum, steep Trendelenburg position (25-45°), and reduced patient access once robot docked. Da Vinci system :...

Special Surgical Techniques3 Feb 2026
ANZCA Final
Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Rocuronium

Rocuronium is an aminosteroid non-depolarizing neuromuscular blocking agent (NMBA) with rapid onset (60-90 seconds) making it suitable for rapid sequence intubation (RSI) when succinylcholine contraindicated....

Muscle Relaxants2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Sciatic Nerve Block

Origin: Formed from : L4-S3 nerve roots (sacral plexus) L4 contribution : From lumbar plexus via lumbosacral trunk Sacral contributions : L5, S1, S2, S3 ventral rami unite in greater sciatic foramen Formation : Within...

Lower Limb Regional3 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+2
ANZCA

Severe Preeclampsia, HELLP Syndrome, and Eclampsia

Severe preeclampsia is defined as preeclampsia with severe features that indicate end-organ dysfunction and increased risk of maternal and fetal complications. It affects 2-8% of pregnancies globally and remains a...

Obstetric Hypertensive Disorders3 Feb 2026
ANZCA Final
Obstetric Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Sevoflurane

Sevoflurane is a fluorinated ether inhalational anaesthetic with blood:gas partition coefficient 0.65 (low solubility), enabling rapid induction and emergence compared to isoflurane (1.4) and halothane (2.4). MAC...

Inhalational Agents2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Sodium Nitroprusside Pharmacology

Sodium nitroprusside (SNP) is a potent, rapid-acting, direct-acting vasodilator that produces arteriolar and venous dilation through non-specific release of nitric oxide (NO). It is a complex inorganic compound...

Direct-Acting Vasodilators3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+2
ANZCA

Spinal Anaesthesia

Spinal anaesthesia involves injection of local anaesthetic into the subarachnoid space producing rapid, dense sensory and motor block with predictable dermatomal distribution. Mechanism: Local anaesthetic acts on...

Regional Techniques2 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Spinal Cord Injury Anaesthesia

Spinal cord injury (SCI) patients present unique challenges due to autonomic denervation, altered drug responses, and multisystem complications. Key principles:

Spinal Cord Injury3 Feb 2026
ANZCA Final
Neuroanaesthesia
A evidence
ANZCA Final Written
+2
ANZCA

Spinal Cord Stimulation - Indications, Trial Period, and Complications

Spinal cord stimulation is a neuromodulation therapy that delivers electrical impulses to the dorsal columns of the spinal cord via implanted electrodes, modulating pain signals before they reach the brain. It is...

Neuromodulation3 Feb 2026
ANZCA Final
Pain Medicine
A evidence
ANZCA Final Written
+1
ANZCA

Spinal Injury Anaesthesia in Trauma

Acute spinal cord injury requires immediate spinal protection, cardiovascular stabilisation, and prevention of secondary injury. Key principles:

Trauma Spinal Surgery3 Feb 2026
ANZCA Final
Trauma Anaesthesia
A evidence
ANZCA Final Written
+2
ANZCA

Strabismus Surgery - Oculocardiac Reflex, PONV, and Suxamethonium Alternatives

Strabismus surgery (squint surgery) is one of the most common paediatric surgical procedures , correcting misalignment of the eyes by tightening, loosening, or repositioning extraocular muscles. It is typically...

Paediatric Surgery3 Feb 2026
ANZCA Final
Paediatric Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Sugammadex Pharmacology

Sugammadex is a modified gamma-cyclodextrin designed specifically to encapsulate and inactivate steroidal neuromuscular blocking agents (rocuronium vecuronium pancuronium), providing rapid and complete reversal of...

Neuromuscular Block Reversal Agents31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Supraclavicular Brachial Plexus Block

Location: Level : Divisions of brachial plexus (after trunks, before cords) Position : Posterior and lateral to subclavian artery, superior to first rib, inferior to clavicle Space : Interscalene groove continues,...

Regional2 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Suxamethonium (Succinylcholine)

Suxamethonium (succinylcholine) is the only depolarizing neuromuscular blocker in clinical use, providing rapid onset (30-60 seconds) and ultra-short duration (5-10 minutes) ideal for rapid sequence intubation....

Muscle Relaxants2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Temperature Regulation

Temperature regulation maintains core temperature 36.5-37.5°C through balance of heat production, conservation, and loss, regulated by the hypothalamus. Heat production: Basal metabolic rate (BMR, 80 W at rest),...

Physiology2 Feb 2026
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Thermoregulation

The hypothalamus serves as the central thermoregulatory integrator, functioning as a biological thermostat with remarkable precision. The preoptic anterior hypothalamus (POAH) contains warm-sensitive neurons that fire...

Integrative Physiology31 Jan 2025
ANZCA Primary
Physiology
High evidence
ANZCA Primary Written
+1
ANZCA

Thiopentone (Thiopental) Pharmacology

Thiopentone (thiopental sodium) is a thiobarbiturate intravenous anaesthetic agent that was the original gold standard for anaesthetic induction for over 50 years before propofol's dominance. Its structure features a...

Intravenous Induction Agents1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Thoracic Anaesthesia

Thoracic anaesthesia requires one-lung ventilation (OLV) for most intrathoracic procedures to provide surgical exposure and protect the dependent lung from contamination. Indications for OLV: Thoracotomy (lobectomy,...

Cardiothoracic2 Feb 2026
ANZCA Final
Thoracic Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Total Intravenous Anaesthesia (TIVA) and Target Controlled Infusion (TCI)

Total intravenous anaesthesia (TIVA) provides complete anaesthesia without volatile agents using continuous IV drug infusions, offering advantages in PONV reduction (50% lower than volatiles), neurosurgery (reduced...

General Clinical2 Feb 2026
ANZCA Final
Pharmacology
High evidence
ANZCA Final Written
+1
ANZCA

Tracheo-Oesophageal Fistula (TOF)

TOF is a congenital anomaly where the trachea and oesophagus fail to separate during embryological development, creating abnormal connections. Oesophageal atresia (OA) is usually present. Key anaesthetic principles:

Congenital Anomalies3 Feb 2026
ANZCA Final
Paediatric Anaesthesia
A evidence
ANZCA Final Written
+1
ANZCA

Tranexamic Acid Pharmacology

Tranexamic acid (TXA) is a synthetic lysine analogue antifibrinolytic agent that competitively inhibits plasminogen activation by blocking lysine-binding sites, thereby preventing fibrin clot degradation. TXA is...

Antifibrinolytic Agents31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Transversus Abdominis Plane (TAP) Block

The TAP block provides analgesia to the anterior abdominal wall (T7-L1 dermatomes) by depositing local anaesthetic in the transversus abdominis plane between internal oblique and transversus abdominis muscles where...

Regional Techniques2 Feb 2026
ANZCA Final
Regional Anaesthesia
High evidence
ANZCA Final Written
+1
ANZCA

Traumatic Brain Injury: Secondary Injury Prevention and Neuroprotection

Traumatic brain injury (TBI) management focuses on preventing secondary brain injury caused by hypotension, hypoxia, hypercapnia, and intracranial hypertension. Cerebral perfusion pressure (CPP) should be maintained...

3 Feb 2026
ANZCA Final
Neuroanaesthesia
+1
ANZCA

Vaporizers

Vaporizers convert liquid volatile anaesthetic agents into vapor for delivery to patients, requiring precise concentration control under varying conditions. Types: Variable bypass (most common, Tec type), measured...

Anaesthetic Equipment2 Feb 2026
ANZCA Primary
Equipment
High evidence
ANZCA Primary Written
+1
ANZCA

Vasopressin and Analogues Pharmacology

Vasopressin (arginine vasopressin, AVP), also known as antidiuretic hormone (ADH), is an endogenous nonapeptide synthesised in the hypothalamic supraoptic and paraventricular nuclei and released from the posterior...

Cardiovascular Pharmacology31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1
ANZCA

Vecuronium: Pharmacology and Clinical Use

Vecuronium is an intermediate-acting aminosteroid non-depolarizing neuromuscular blocker . Structure : Steroid nucleus with quaternary ammonium groups (bisquaternary). Mechanism : Competitive antagonist at nicotinic...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
ANZCA

Venous Air Embolism - Detection and Management

Immediate Recognition: Sudden drop in EtCO2 (earliest sign) 2 mmHg drop from baseline Mill wheel murmur on precordial Doppler (characteristic churning sound) Sudden cardiovascular collapse during sitting position...

Anaesthetic Crisis Management3 Feb 2026
Anaesthesia
ANZCA Final
A - Evidence-Based Guidelines evidence
ANZCA Final Written
ANZCA

Ventricular Assist Device Implantation

Ventricular assist device (VAD) implantation is a major cardiac surgical procedure for patients with end-stage heart failure. The three configurations are: (1) Left VAD (LVAD) - most common (80%), blood inflow from...

Cardiac Surgery3 Feb 2026
Anaesthesia
Cardiothoracic Surgery
A evidence
ANZCA Final Examination